Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study
Alessandra Bettiol,Maria Letizia Urban,Roberto Padoan,Matthieu Groh,Giuseppe Lopalco,Allyson Egan,Vincent Cottin,Paolo Fraticelli,Claudia Crimi,Stefano Del Giacco,Laura Losappio,Laura Moi,Francesco Cinetto,Marco Caminati,Pavel Novikov,Alvise Berti,Paolo Cameli,Pascal Cathébras,Angelo Coppola,Cécile-Audrey Durel,Marco Folci,Alberto Lo Gullo,Carlo Lombardi,Sara Monti,Paola Parronchi,Carlos Martinez Rivera,Roser Solans,Angelo Vacca,Georgina Espígol-Frigolé,Gabriella Guarnieri,Fulvia Chieco Bianchi,Maria Rita Marchi,Colas Tcherakian,Jean-Emmanuel Kahn,Florenzo Iannone,Vincenzo Venerito,Charlene Desaintjean,Gianluca Moroncini,Santi Nolasco,Giulia Anna Maria Luigia Costanzo,Jan Walter Schroeder,Camillo Ribi,Michelangelo Tesi,Elena Gelain,Irene Mattioli,Federica Bello,David Jayne,Domenico Prisco,Augusto Vaglio,Giacomo Emmi,European EGPA Study Group
DOI: https://doi.org/10.1016/S2665-9913(23)00243-6
Abstract:Background: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients with EGPA. Methods: This retrospective cohort study included patients with EGPA from 28 European referral centres of the European EGPA Study Group across six countries (Italy, France, UK, Russia, Spain, and Switzerland) who received benralizumab as any line of treatment between Jan 1, 2019, and Sep 30, 2022. We assessed the rates of complete response, defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] of 0) and a prednisone dose of up to 4 mg/day, in contrast to partial response, defined as a BVAS of 0 and a prednisone dose greater than 4 mg/day. Active disease manifestations, pulmonary function, variation in glucocorticoid dose, and safety outcomes were also assessed over a 12-month follow-up. Findings: 121 patients with relapsing-refractory EGPA treated with benralizumab at the dose approved for eosinophilic asthma were included (64 [53%] women and 57 [47%] men; median age at the time of beginning benralizumab treatment 54·1 years [IQR 44·2-62·2]). Complete response was reported in 15 (12·4%, 95% CI 7·1-19·6) of 121 patients at month 3, 25 (28·7%, 19·5-39·4) of 87 patients at month 6, and 32 (46·4%, 34·3-58·8) of 69 patients at month 12; partial response was observed in an additional 43 (35·5%, 27·0-44·8) patients at month 3, 23 (26·4%, 17·6-37·0) at month 6, and 13 (18·8%, 10·4-30·1) at month 12. BVAS dropped from 3·0 (IQR 2·0-8·0) at baseline to 0·0 (0·0-2·0) at months 3 and 6, and to 0·0 (0·0-1·0) at month 12. The proportion of patients with systemic manifestations, active peripheral neurological disease, ear, nose, and throat involvement, and pulmonary involvement decreased, with an improvement in lung function tests. Six patients relapsed after having a complete response. The oral prednisone (or equivalent) dose decreased from 10·0 mg/day (5·0-12·5) at baseline to 5·0 mg/day (3·6-8·5) at month 3 (p<0·01), to 5·0 mg/day (2·5-6·3) at month 6, and to 2·5 mg/day (0·0-5·0) at month 12 (p<0·0001). 19 (16%) of 121 patients had adverse events and 16 (13%) discontinued benralizumab. Interpretation: These data suggest that benralizumab could be an effective treatment for EGPA in real-life clinical practice. Further clinical trials are required to confirm the efficacy of benralizumab in patients with a higher baseline disease activity. Funding: None.